My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

39 40 Next >

This New York-Based Digital Therapeutics Company Looks To Disrupt a $475 Billion Market ↗

July 07, 2022

As the global coronavirus pandemic forced people to keep their distance from one another, there has been an increase in the adoption of digital health solutions among healthcare professionals and...

Via Benzinga

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

July 05, 2022

From The Schall Law Firm

Via Business Wire

The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study ↗

July 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold ↗

June 30, 2022

The company was testing the drug in multiple sclerosis and myasthenia gravis.

Via Investor's Business Daily

Why Sanofi Shares Are Falling Today ↗

June 30, 2022

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

July 01, 2022

From The Schall Law Firm

Via Business Wire

How Is The Market Feeling About Sanofi? ↗

July 01, 2022

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline' ↗

June 29, 2022

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,...

Via Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients ↗

June 29, 2022

Via Benzinga

Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes ↗

June 24, 2022

The companies' shot was more than 93% effective in previously infected people.

Via Investor's Business Daily

Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24 ↗

June 24, 2022

Reuters

Via Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron ↗

June 24, 2022

Via Benzinga

This Pharmaceutical Company Is Moving Beyond CBD ↗

June 23, 2022

The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge...

Via Benzinga

Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry ↗

June 21, 2022

Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc.

Via Benzinga

Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes ↗

June 17, 2022

Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session.

Via InvestorPlace

Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors ↗

June 14, 2022

Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target.

Via InvestorPlace

Morning Brief: Top Financial Stories Dominating on Monday, June 13 ↗

June 13, 2022

CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why

Via Benzinga

Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern ↗

June 13, 2022

Via Benzinga

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit ↗

June 10, 2022

The conversation around obesity is changing. Two diabetes drug makers are at the forefront.

Via Investor's Business Daily

Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)

June 09, 2022

Via AB Newswire

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗

June 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children ↗

June 07, 2022

The U.S.

Via Benzinga

CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment ↗

June 07, 2022

Key Takeaways: CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending Appointment of chairman with close ties...

Via Benzinga

Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)

June 06, 2022

Via AB Newswire

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗

June 05, 2022

Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.

Via Benzinga

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer ↗

June 02, 2022

Regeneron secured the global rights to Sanofi-partnered Libtayo.

Via Investor's Business Daily

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.